



THE CANCER DRUG DEVELOPMENT FORUM

FACILITATE. DEBATE. ACTIVATE. INNOVATE.

Promoting Multi-Stakeholder Collaboration
to Advance Oncology Therapeutics.

 info@cddf.org

 www.cddf.org

◎ WHAT IS THE CDDF

The Cancer Drug Development Forum (CDDF) is a **non-profit organisation** registered in **Belgium** that provides a **neutral platform** to stimulate **interaction between stakeholders** involved in **cancer drug development**.

◎ OUR MISSION

The CDDF's mission is to **facilitate collaboration between stakeholders**, to **increase efficiency in cancer drug development**, and **accelerate the delivery of effective oncology treatment** to patients.

◎ HOW WE ADVANCE OUR MISSION

- ▶ The CDDF provides a **non-competitive, non-commercial platform** for **multi-stakeholder discussions** and **collaboration**
- ▶ The CDDF **brings together all actors** in the oncology community such as **academia**, the **healthcare industry**, **regulatory authorities**, **health technology assessment (HTA) bodies**, **policymakers**, and **patient advocacy groups**
- ▶ The CDDF **stimulates advancement and innovation** in the field through **scientific debate** and **open discussion**

INITIATIVES

For many years, the Cancer Drug Development Forum (CDDF) has stimulated discussions to **accelerate effective drug development** in oncology treatment, as well as shorten the time to market, and to patient access.

The CDDF offers workshops, conferences and webinars, which bring together stakeholders involved in cancer drug development to **a productive dialogue in a neutral, non-competitive space**.

The association drives multiple activities and initiatives in **close contact with regulators** from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), additional national regulatory agencies, **HTAs, academic researchers** from around the globe, **healthcare companies**, and **patient advocates**.





FACILITATE. DEBATE. ACTIVATE. INNOVATE.

The Cancer Drug Development Forum (CDDF) **Annual Conference** is a unique meeting which facilitates open, meaningful dialogue. This multi-stakeholder, interactive, three-day gathering, offers plenary lectures with moderated discussions, including case studies and networking opportunities.

The agile, responsive nature of the CDDF platform allows **programs to be quickly initiated or adapted to reflect current and pressing issues**. The CDDF has also clearly proved to be a **visionary force within the cancer drug development field** addressing topics such as immuno-oncology, real-world data in cancer drug development, histology independent drug development, MRT & ctDNA in oncology, diversity in oncology clinical trials, and the combination of immunotherapy and radiotherapy.

The CDDF continues to **pioneer progress in cancer drug treatments** through workshops and webinars exploring topics affecting the future of cancer care, such as real-world evidence, decentralised care and trials, drug and biomarker combinations, clinical research in Central and Eastern Europe, and innovation in rare cancers.

The association also publishes **executive summaries, white papers, and meeting reports** from workshops discussions, conference presentations, and lecture briefings in order **to increase knowledge of the challenges and opportunities in cancer drug development**.



**CDDF MEETINGS BRING
TOGETHER REGULATORS,
HTAs, THE HEALTHCARE
INDUSTRY, ACADEMICS, AND
PATIENT ADVOCATES TO
COLLABORATE**

**INCLUSIVE &
COLLABORATIVE NETWORK
OF MULTI-STAKEHOLDERS
INVOLVED IN ONCOLOGY
DRUG DEVELOPMENT**

CDDF LEADERSHIP

The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs, representing a range of perspectives within the drug development process.

These distinguished academics are experienced pre-clinical and clinical investigators, medical oncologists, statistician, regulatory scientists, and pharmacists who have experience working within regulatory agencies, the pharmaceutical industry, and patient advocacy.

The chairperson and directors are elected for a period of three years.

CDDF BOARD OF DIRECTORS



**Ruth
Plummer**

Chairperson



**Stefan
Symeonides**

Vice-Chairperson



**Axel
Glasmacher**

Treasurer



**Jaap
Verweij**

Managing Director



**Catarina
Edfjaell**



**Mark
Lawler**



**Eva
Skolvlund**



**Rosa
Giuliani**



**Christian
Schneider**



**Fergus
Sweeney**

CDDF OFFICE

CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.



**Thierry
Coppens**

Director of
Operations



**Giorgia
Campagnano**

Event Manager



**Shannon
Adeux**

Event Coordinator



**Nina
Davidova**

Community &
Communication
Coordinator



CDDF ACTIVITIES 2025

Click the buttons to view detailed information

MULTI-STAKEHOLDER DISCUSSIONS

Cancer Drug Development Forum (CDDF)

ANNUAL CONFERENCE 2025

**Challenges, Advances,
and Open Questions in
Global Cancer Drug
Development and
Clinical Trials**

3-5 February 2025
Noordwijk aan Zee, NL



[Programme](#)

[Executive
Summary](#)



MULTI-STAKEHOLDER WORKSHOP

**New Modalities in
Cancer Drug
Development**

31 March - 1 April 2025
Brussels, BE (hybrid)



[Programme](#)

[Executive
Summary](#)



MULTI-STAKEHOLDER WORKSHOP

**Accelerating drug
development
to deliver better
patient care**

17 - 18 November 2025
Brussels, BE (hybrid)



[Programme](#)

[Registration](#)



AAADV-ASCO-CDDF Workshop
Global Oncology Drug Development

15-16 May 2025, Washington D.C. (US)

(Available soon)

CDDF ACTIVITIES 2025

CDDF WEBINAR SERIES

EU HTA Regulation (2025)

Concluded



AI and Big Data AI in Drug Development:
Using AI in assessing cancer treatment response on imagine: Project
Data Sphere

Concluded



Bayesian Framework:
Bayesian Approaches in Oncology Drug Development: Introduction
and Motivations

Concluded



.....

SAVE THE DATE

AI and Big Data AI in drug development:
Transformation of future clinical trials using AI-enhanced imaging
biomarkers

18/09/2025



SAVE THE DATE

Long term outcomes of in utero exposure to
cytotoxic therapy: Is involving pregnant patients an absolute no-go in
cancer drug development?

04/12/2025



SAVE THE DATE

ACT EU Series: Overview of ACT EU (2025)

15/12/2025



MEETING OUTCOMES 2024

Click the buttons to view meeting outputs

- **CDDF Annual Conference 2024: Changing paradigms to accelerate oncology drug development** (5 – 7 February 2024, NL)

[Executive summary](#)

[White paper](#)

[Recordings/slides](#)

- **Multi-Stakeholder Workshop in Central and Eastern Europe: New Approaches for the Next Level of Development** (15 – 16 April 2024, PL)

[Executive summary](#)

[White paper
\(available soon\)](#)

[Recordings/slides](#)

- **ESMO Congress 2024: ESMO-CDDF Educational Session: Regulatory Challenges in Clinical Cancer Drug Development** (16 September 2024, SP)

[Executive summary](#)

[White paper
\(available soon\)](#)

- **CDDF&EORTC Multi-Stakeholder joint Workshop: Innovation and Access in Rare Cancers** (23-24 September 2024, NL)

[Executive summary](#)

[White paper
\(available soon\)](#)

[Recordings/slides](#)

**Recent meeting recordings and slides are accessible exclusively to the CDDF Industry Members, the CDDF Full Association Member, Patient Advocates, HTAs, and regulators (FDA, EMA, HTAs and national agencies) for educational purposes*

MEETING OUTCOMES 2024

Click the buttons to view meeting outputs

CDDF Live Webinar: COVID-19 and Cancer: Time for a Reset to repair the damage done
(15 January 2024)

[Key takeaways](#)

[Recordings/slides](#)

CDDF Live Webinar: Clinical Research in Central and Eastern Europe: Realising the opportunities
(12 February 2024)

[Key takeaways](#)

[Recordings/slides](#)

CDDF Live Webinar: Cancer Medicines Forum: Advancing Cancer Treatment Optimization Across Europe
(25 June 2024)

[Key takeaways](#)

[Recordings/slides](#)

CDDF Live Webinar: Bayesian Approaches in Drug Development
(11 July 2024)

[Key takeaways](#)

[Recordings/slides](#)

CDDF Live Webinar series: AI and Big Data in Cancer Drug Development
An introduction to the use of AI in cancer drug development and regulatory considerations
(29 October 2024)

[Key takeaways](#)

[Recordings/slides](#)

CDDF Live Webinar: EU Clinical Trial Regulations
(12 November 2024)

[Key takeaways](#)

[Recordings/slides](#)




COLLABORATION AND OPEN DIALOGUE AMONG ALL STAKEHOLDERS ARE KEY TO IMPROVING OUTCOMES FOR CANCER PATIENTS


 info@cddf.org

 www.cddf.org

 [@cddf_eu](https://twitter.com/cddf_eu)

 [The Cancer Drug Development Forum \(CDDF\)](https://www.linkedin.com/company/cddf/)

 Cancer Drug Development Forum asbl
Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium

 The CDDF is a non-profit association in the register of legal entities at the French
Speaking Enterprise Court in Brussels. Enterprise number: 738.523.752